The results are in, Pharvaris announced positive topline data, stock surges 27%

Pharvaris (NASDAQ: PHVS) shares rose 27% Tuesday after the company announced positive topline data from its CHAPTER 3 pivotal Phase 3 study of deucrictibant XR for the prevention of hereditary angioedema (HAE) attacks.

The study met its primary endpoint, showing an 83% attack rate reduction versus placebo. The company said CHAPTER 3 is the first and only prophylaxis Phase 3 study to evaluate all three types of HAE. In people with HAE Type 1 or Type 2, the treatment showed an 87% attack rate reduction versus placebo.

The global Phase 3, double-blind, placebo-controlled study evaluated orally administered deucrictibant XR tablet at 40 mg once daily for the prevention of attacks in adolescents and adults with HAE. The study randomized 85 participants from 21 countries in a 2:1 ratio to deucrictibant XR or placebo for 24 weeks of treatment.

All secondary efficacy endpoints were met with statistical significance. The treatment was well tolerated with most treatment-emergent adverse events being mild or moderate. There were no treatment-related serious adverse events reported. One participant in each group discontinued treatment due to an adverse event.